Denali Therapeutics Inc. (DNLI): Price and Financial Metrics


Denali Therapeutics Inc. (DNLI)

Today's Latest Price: $41.14 USD

0.22 (0.54%)

Updated Oct 23 4:00pm

Add DNLI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DNLI Stock Summary

  • DNLI's price/sales ratio is 151.6; that's higher than the P/S ratio of 97.82% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Denali Therapeutics Inc is reporting a growth rate of 289.15%; that's higher than 95.12% of US stocks.
  • As for revenue growth, note that DNLI's revenue has grown -79.5% over the past 12 months; that beats the revenue growth of just 1.81% of US companies in our set.
  • Stocks that are quantitatively similar to DNLI, based on their financial statements, market capitalization, and price volatility, are PRQR, ARGX, FATE, NKTR, and XNCR.
  • DNLI's SEC filings can be seen here. And to visit Denali Therapeutics Inc's official web site, go to www.denalitherapeutics.com.

DNLI Stock Price Chart Interactive Chart >

Price chart for DNLI

DNLI Price/Volume Stats

Current price $41.14 52-week high $45.82
Prev. close $40.92 52-week low $12.39
Day low $39.09 Volume 360,700
Day high $41.37 Avg. volume 640,516
50-day MA $36.17 Dividend yield N/A
200-day MA $26.46 Market Cap 4.36B

Denali Therapeutics Inc. (DNLI) Company Bio


Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.


DNLI Latest News Stream


Event/Time News Detail
Loading, please wait...

DNLI Latest Social Stream


Loading social stream, please wait...

View Full DNLI Social Stream

Latest DNLI News From Around the Web

Below are the latest news stories about Denali Therapeutics Inc that investors may wish to consider to help them evaluate DNLI as an investment opportunity.

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ...

Benzinga | September 15, 2020

Denali Therapeutics (DNLI) Investor Presentation - Slideshow

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 14, 2020

MedGenome announces Strategic Collaboration in Parkinson's Disease with Denali Therapeutics

FOSTER CITY, California, Aug. 26, 2020 /PRNewswire/ -- MedGenome, a leading genomic diagnostics, research and data company based in Foster City, CA and Bangalore, India, today announced that it has formed a strategic discovery collaboration focused on novel discoveries in Parkinson's…

PR Newswire | August 26, 2020

Read More 'DNLI' Stories Here

DNLI Price Returns

1-mo 18.25%
3-mo 77.86%
6-mo 73.88%
1-year 153.95%
3-year N/A
5-year N/A
YTD 136.17%
2019 -15.68%
2018 32.10%
2017 N/A
2016 N/A
2015 N/A

Continue Researching DNLI

Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:

Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7021 seconds.